178 results on '"Kramolowsky, Eugene"'
Search Results
2. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin[FIGURE DASH]Unresponsive Nonmuscle-Invasive Bladder Cancer
3. Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer
4. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes
5. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
6. Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained
7. Providing Access to Care through a 24-Hour Dedicated Stone Line
8. MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)
9. A phase II clinical study of intravesical photo dynamic therapy in patients with BCG-unresponsive NMIBC (interim analysis).
10. Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG.
11. IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
12. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results.
13. Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
14. PLLBA-01 FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS
15. Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.
16. POST VASECTOMY SEMEN ANALYSIS: DOES PATIENT CONVENIENCE IMPROVE COMPLIANCE?: MP37-20
17. MP28-06 COST ANALYSIS OF FLEXIBILE URETEROSOPE REPAIRS: EVALUATION OF 655 PROCEDURES IN A COMMUNITY-BASED PRACTICE EXPERIENCE
18. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3‐year trial results
19. PD18-06 AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA IN LARGE PROSTATES (80-150CC): 3-YEAR RESULTS
20. UTILIZATION OF 24 HOUR PHONE ACCESS FOR PATIENTS WITH ACUTE URINARY CALCULI: PD28-05
21. Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
22. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results
23. PD56-05 THREE-YEAR OUTCOMES AFTER AQUABLATION COMPARED TO TURP: EFFICACY AND EJACULATORY IMPROVEMENTS SUSTAINED
24. MP25-10 AQUABLATION FOR BENIGN PROSTATIC HYPERPLASIA IN LARGE PROSTATES (80-150CC)
25. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial
26. Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial
27. WATER II (80-150 mL) procedural outcomes
28. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation ® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
29. Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial.
30. MP37-20 POST VASECTOMY SEMEN ANALYSIS: DOES PATIENT CONVENIENCE IMPROVE COMPLIANCE?
31. Cost Analysis of Flexible Ureteroscope Repairs: Evaluation of 655 Procedures in a Community-Based Practice
32. WATER II (80–150 mL) procedural outcomes.
33. PD28-05 UTILIZATION OF 24 HOUR PHONE ACCESS FOR PATIENTS WITH ACUTE URINARY CALCULI
34. 421 IMPACT OF REIMBURSEMENT ON PROSTATE CANCER TREATMENT IN COMMUNITY UROLOGY PRACTICE ANALYSIS OF 1995-2010 LONGITUDINAL DATABASE
35. Clinical and Economic Impact of Implementation of Slow Shockwave Lithotripsy for the Treatment of Urinary Calculi
36. 1464 CLINICAL AND ECONOMIC IMPACT OF IMPLEMENTATION OF SLOW SHOCK WAVE LITHOTRIPSY FOR THE TREATMENT OF URINARY CALCULI
37. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer
38. Editorial: New Approaches to Old Diseases
39. Editorial
40. Impact of Physician Awareness on Hospital Charges for Radical Retropubic Prostatectomy
41. Color Doppler Ultrasound for the Diagnosis of Segmental Testicular Infarction
42. The interaction between electrosurgical generators, endoscopic electrodes, and tissue
43. The Urological Application of Electrosurgery
44. Endourological Treatment of Ureteroenteric Anastomotic Strictures: Long-Term Followup
45. Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures
46. Comparison of Formalin-Induced Porcine Ureteral Strictures with Human Ureteral Strictures.
47. Percutaneous transperineal placement of gold 198 seeds for treatment of carcinoma of the prostate.
48. Endourological Management of Ureteroileal Anastomotic Strictures: Is It Effective?
49. Management of Ureterointestinal Anastomotic Strictures: Comparison of Open Surgical and Endourological Repair
50. Advances in Endosurgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.